BackBiomarin Pharmaceutical - Registered Shares Overview
Biomarin Pharmaceutical Inc. - Registered Shares

Biomarin Pharmaceutical - Registered Shares Target Price

See Biomarin Pharmaceutical - Registered Shares's analyst price targets ($89) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$64.67

Average Target Price

$88.8237.4% upside

17 analysts in the last 4 months

High: $124 | Low: $50

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-26UBS$8836.1% upsideOpen
2026-08-18BMO CapitalDavid Lebowitz$9851.6% upsideOpen
2026-08-18H.C. Wainwright$598.8% downsideOpen
2026-08-17Piper Sandler$8836.1% upsideOpen
2026-08-17BarclaysEliana Merle$11171.7% upsideOpen
2026-08-10Canaccord GenuityWhitney Ijem$11476.3% upsideOpen
2026-08-07Raymond James$10562.4% upsideOpen
2026-08-07Morgan Stanley$12491.8% upsideOpen
2026-08-07Stifel Nicolaus$708.3% upsideOpen
2026-08-07OppenheimerLeland Gershell$9750% upsideOpen
2026-07-07RBC CapitalLuca Issi$624.1% downsideOpen
2026-05-22Canaccord Genuity$11171.7% upsideOpen
2026-05-18Leerink Partners$624.1% downsideOpen
2026-05-18H.C. Wainwright$5022.7% downsideOpen
2026-05-11Goldman Sachs$696.7% upsideOpen
2026-05-05Evercore ISI$12085.6% upsideOpen
2026-05-05Tudor PickeringWilliam Pickering$8226.8% upsideOpen
2026-04-27Morgan StanleySean Laaman$12085.6% upsideOpen
2026-03-12JefferiesAkash Tewari$10359.3% upsideOpen
2026-03-03BarclaysEliana Merle$10562.4% upsideOpen
2026-03-02Loop Capital MarketsIlya Zubkov$10562.4% upsideOpen
2026-02-26Canaccord GenuityWhitney Ijem$10460.8% upsideOpen
2026-02-24Oppenheimer$9546.9% upsideOpen
2026-02-24Stifel NicolausPaul Matteis$685.2% upsideOpen
2026-02-18Wells Fargo$7516% upsideOpen
2026-02-06Piper Sandler$8429.9% upsideOpen
2026-01-20Canaccord Genuity$9851.6% upsideOpen
2025-12-23Truist FinancialJoon Lee$10054.6% upsideOpen
2025-12-22H.C. Wainwright$607.2% downsideOpen
2025-12-03Leerink Partners$607.2% downsideOpen
2025-11-03Tudor PickeringWilliam Pickering$8836.1% upsideOpen
2025-11-03Bernstein$8836.1% upsideOpen
2025-10-28RBC CapitalLuca Issi$662.1% upsideOpen
2025-10-28Stifel Nicolaus$7312.9% upsideOpen
2025-10-28Truist FinancialJoon Lee$8023.7% upsideOpen
2025-10-28Morgan StanleySean Laaman$9851.6% upsideOpen
2025-10-28H.C. Wainwright$5514.9% downsideOpen
2025-10-28Wells FargoMohit Bansal$708.3% upsideOpen
2025-10-28Barclays$8023.7% upsideOpen
2025-08-05UBS$11476.3% upsideOpen
2025-07-15Wolfe ResearchAkash Tewari$9546.9% upsideOpen
2024-10-30Cantor FitzgeraldOlivia Brayer$9039.2% upsideOpen
2024-10-30Robert W. BairdJack Allen$650.5% upsideOpen
2024-10-30CitigroupDavid Lebowitz$8125.3% upsideOpen
2024-10-10Raymond JamesDanielle Brill$7922.2% upsideOpen
2024-10-04BarclaysGena Wang$8633% upsideOpen
2024-09-18CitigroupDavid Lebowitz$9343.8% upsideOpen
2024-09-17ScotiabankGeorge Farmer$7820.6% upsideOpen
2024-09-17Truist FinancialJoon Lee$9039.2% upsideOpen
2024-09-17BernsteinWilliam Pickering$9039.2% upsideOpen

Biomarin Pharmaceutical - Registered Shares (BMRN) FAQ

Biomarin Pharmaceutical - Registered Shares (BMRN) currently reports a target price of $89. Use the charts on this page to explore Biomarin Pharmaceutical - Registered Shares's target price history and peer comparisons.

Analysts' average 12-month price target for Biomarin Pharmaceutical - Registered Shares is $89, about 37.4% upside from the current share price of $64.67. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $89, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Biomarin Pharmaceutical - Registered Shares, and consider following BMRN for alerts when major investors trade the stock.

Biomarin Pharmaceutical - Registered Shares is classified in the Healthcare sector. On target price, it currently shows $89. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BMRN with unrelated industries.